At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Nicotinamide +1 moredrug
Likely dose
Nicotinamide 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia
In Brief
A Phase 2 clinical trial evaluating Nicotinamide and Placebo Comparator for Alzheimer's Disease and Mild Cognitive Impairment. Completed, enrolled 46 participants across 2 sites.
Detailed Summary
The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Mild Cognitive Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartJul 2017
Primary CompletionAug 2022
TodayJul 2026
First PostedFeb 23, 2017
Enrollment StartJul 12, 2017
Primary CompletionAug 30, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.4 years ago
Interventions
Nicotinamidedrug
Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
Placebo Comparatordrug
Oral Tablet